GSK Announces Joint Venture for Pediatric Vaccine - - BioPharm International

ADVERTISEMENT

GSK Announces Joint Venture for Pediatric Vaccine



GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.

If the vaccine is approved, it will combine GSK’s injectable polio vaccine and Biological E’s pentavalent vaccine for diphtheria, tetanus, whooping cough, hepatitis B and Haemophilus influenzae type B, and could be the first vaccine of its type, according to a GSK press statement.

The vaccine is intended to reduce the number of injections for children and to improve compliance with immunization schedules. Space at local storage facilities would also be freed up because the vaccine is intended to be a fully liquid, ready-to-use formulation with no need for additional ingredients or materials. Phase I development is expected to start in the next two years.

Each company will have a 50% stake in the joint venture and will bear the development costs. A small cash investment will be made by both companies to cover the start-up costs and further development costs will be split equally.

Completion of the transaction is expected later this year.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here